Physician profile
James M Ohrt
NPI 1447279732
$2,514.53
in general payments reported to CMS, 2019-2025
36 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2020: $497 · 2021: $597 · 2022: $266 · 2023: $324 · 2024: $376 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $838.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $290.03 | 2019-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $288.33 | 2021-2025 | |
| Pfizer INC. | $280.01 | 2019-2024 | |
| Amgen INC. | $211.43 | 2019-2024 | Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $140.89 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.94 | 2019-2022 | |
| Astellas Pharma US INC | $114.60 | 2019-2024 | Veozah |
| Aimmune Therapeutics, INC. | $113.51 | 2024 | |
| Allergan, INC. | $102.50 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.47 | 2020-2023 | Xifaxan |
| Axsome Therapeutics, INC. | $82.02 | 2023-2025 | Auvelity |
| Lilly USA, LLC | $80.90 | 2020-2025 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $53.42 | 2020-2024 | Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $44.66 | 2020-2021 | |
| Glaxosmithkline, LLC. | $43.79 | 2020-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $41.24 | 2020-2021 | |
| Philips North America LLC | $40.18 | 2020-2022 | |
| Medicure Pharma INC. | $36.31 | 2021 | |
| Xeris Pharmaceuticals, INC. | $32.68 | 2023 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company LTD. | $30.59 | 2022 | |
| Mylan Specialty L.P. | $29.24 | 2020 | |
| Inspire Medical Systems, INC. | $28.44 | 2025 | Inspire |
| Qol Medical, LLC | $27.41 | 2019 | |
| Merck Sharp & Dohme LLC | $26.57 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $20.02 | 2021 | |
| Biogen, INC. | $17.12 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.04 | 2021 | |
| Acadia Pharmaceuticals INC | $15.04 | 2021 | |
| Exact Sciences Corporation | $14.90 | 2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $14.30 | 2021 | |
| Kyowa Kirin, INC. | $14.26 | 2023 | Crysvita |
| Abbott Laboratories | $13.25 | 2022 | |
| Dexcom, INC. | $13.12 | 2023 | Dexcom G6 Transmitter |
| Ultragenyx Pharmaceutical INC. | $12.76 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.46 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ohrt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.